Arete Therapeutics (Hayward, CA) clinical-stage biotechnology company developing soluble epoxide hydrolase inhibitor small molecule drugs for the treatment of cardiovascular, metabolic and inflammatory diseases, closed a $51M Series A financing. Participants include Frazier Healthcare Ventures, Alta Partners, Burrill & Co., Three Arch Partners, and Altitude Life Science Ventures.